Modality
Small Molecule
MOA
KIF18Ai
Target
FXIa
Pathway
Amyloid
Wet AMDNB
Development Pipeline
Preclinical
Aug 2025
→ Aug 2026
PreclinicalCurrent
NCT08175961
305 pts·NB
2025-08→2026-08·Recruiting
305 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-185mo awayInterim· NB
Trial Timeline
Q42026Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2026-08-18 · 5mo away
NB
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08175961 | Preclinical | NB | Recruiting | 305 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| TAK-1836 | Takeda | Preclinical | EGFR |